Markets:

Overview

News

Currencies

International

Treasuries

UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

22.05 -0.66 (-2.93%)

Streaming Delayed Price Updated: 1:44 PM EST, Jan 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about UroGen Pharma Ltd. - Ordinary Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments

March 16, 2023

From UroGen Pharma Ltd.

Via Business Wire

Earnings Scheduled For March 16, 2023 ↗

March 16, 2023

Companies Reporting Before The Bell • KVH Industries (NASDAQ:KVHI) is projected to report quarterly earnings at $0.03 per share on revenue of $34.29 million.

Via Benzinga

UroGen Pharma Earnings Preview ↗

March 15, 2023

Via Benzinga

UroGen Pharma to Report Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 16, 2023

March 09, 2023

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma's Return On Capital Employed Overview ↗

December 20, 2022

Via Benzinga

Earnings Scheduled For August 11, 2022 ↗

August 11, 2022

Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.

Via Benzinga

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 06, 2023

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Present at Upcoming Investor Conferences

March 01, 2023

From UroGen Pharma Ltd.

Via Business Wire

Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer

February 15, 2023

From UroGen Pharma Ltd.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For February 8, 2023 ↗

February 08, 2023

Via Benzinga

Results of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer

January 11, 2023

From UroGen Pharma Ltd.

Via Business Wire

UroGen Completes Enrollment of Its Phase 3 Clinical Trial for UGN-102 in Development for Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

December 19, 2022

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

December 09, 2022

From UroGen Pharma Ltd.

Via Business Wire

UroGen Announces New Data from the OPTIMA II Study that Show Median Durability of Response of 24.4 Months for UGN-102, an Investigational Non-Surgical Chemoablative Treatment for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer

December 02, 2022

From UroGen Pharma Ltd.

Via Business Wire

UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper Tract Urothelial Cancer

December 01, 2022

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Present at Evercore ISI 5th Annual Virtual HealthCONx Conference

November 21, 2022

From UroGen Pharma Ltd.

Via Business Wire

UroGen Highlights New Real-World Safety Data Published in The British Journal of Urology International That Showed a Low Rate of Ureteral Stenosis When Antegrade Administration of JELMYTO® was Used in Patients with Upper Tract Urothelial Carcinoma

November 14, 2022

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

November 10, 2022

From UroGen Pharma Ltd.

Via Business Wire

Earnings Scheduled For November 10, 2022 ↗

November 10, 2022

Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report earnings for its third quarter.

Via Benzinga

UroGen Announces the Appointment of Dan Wildman to the UroGen Pharma Board of Directors

November 09, 2022

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022

November 03, 2022

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Host Thought Leader Webinar on UGN-102 and Non-Muscle Invasive Bladder Cancers

October 11, 2022

From UroGen Pharma Ltd.

Via Business Wire

FDA Authorizes an Extension of the In-Use Period for UroGen Pharma’s JELMYTO® Admixture to 96 Hours Following Reconstitution

September 28, 2022

From UroGen Pharma Ltd.

Via Business Wire

Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday ↗

September 19, 2022

Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.

Via Benzinga

Why NCR Is Trading Lower By Around 23%, Here Are 42 Stocks Moving In Friday's Mid-Day Session ↗

September 16, 2022

Gainers Kensington Capital Acquisition Corp. IV (NYSE: AMPX) jumped 35.4% to $13.54 after gaining 11% on Thursday.

Via Benzinga

UroGen Announces the Appointment of Dr. Leana S. Wen to the UroGen Pharma Board of Directors

September 12, 2022

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 09, 2022

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Announces Upcoming 2022 Conferences

September 07, 2022

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

August 11, 2022

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022

July 27, 2022

From UroGen Pharma Ltd.

Via Business Wire

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.